bristolmyerssquibb
Bristol-Myers Squibb (NYSE:BMY) posted a modest gain after a double beat on earnings.The company continues to display strong fundamentals and a robust pipeline.Although growth investors may not be pleased, Bristol-Myers Squibb stock remains a strong value stock.Bristol-Myers Squibb Co (NYSE:BMY) posted a small gain after an earnings report; the company beat its top and bottom lines. The pharmaceutical company delivered earnings per share (EPS) of $1.99 on revenue of $11.22 billion. That was better than the analyst forecast for $1.83 EPS on revenue of $11.18 billion. Q3 2022 hedge fund letters,...
ValueWalk
ValueWalk
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら